Lack of effect of the 2C-adrenoceptor Del322-325 polymorphism on inhibition of cyclic AMP production in HEK293 cells

British Journal of Pharmacology

Volumn 159, Issue 4, 2010, Pages 820-830

  Montgomery, M D ^a   Bylund, D B ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

2C; Adenylyl cyclase; Adrenoceptor; Del322 325; Heart failure; Polymorphism; Signalling

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BRIMONIDINE; CLONIDINE; CYCLIC AMP; FORSKOLIN; NORADRENALIN; RADIOLIGAND; ADENYLATE CYCLASE; ADRENERGIC RECEPTOR ALPHA(2C); ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ENZYME ACTIVATOR; QUINOXALINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; GENETIC POLYMORPHISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; BINDING COMPETITION; CELL LINE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; RADIOASSAY; SIGNAL TRANSDUCTION; STATISTICAL MODEL;

ADENYLATE CYCLASE; ADRENERGIC ALPHA-AGONISTS; BINDING, COMPETITIVE; CELL LINE; CLONIDINE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; FORSKOLIN; HUMANS; LINEAR MODELS; NOREPINEPHRINE; POLYMORPHISM, GENETIC; QUINOXALINES; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-2; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77249110771     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00584.x     Document Type: Article

References (44)

1. Adler CH, Meller E, Goldstein M (1987). Receptor reserve at the alpha-2 adrenergic receptor in the rat cerebral cortex. J Pharmacol Exp Ther 240 : 508 515.
2. Agneter E, Singer EA, Sauermann W, Feuerstein TJ (1997). The slope parameter of concentration-response curves used as a touchstone for the existence of spare receptors. Naunyn Schmiedebergs Arch Pharmacol 356 : 283 292.
3. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S et al. (2002). Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106 : 2491 2496.
4. Bristow MR (1998). Why does the myocardium fail? Insights from basic science. Lancet 352 (Suppl. 1 SI8 SI14.
5. Bucheler MM, Hadamek K, Hein L (2002). Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109 : 819 826.
6. Buscher R, Herrmann V, Insel PA (1999). Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci 20 : 94 99.
7. Chaudhry A, Granneman JG (1994). Influence of cell type upon the desensitization of the beta 3-adrenergic receptor. J Pharmacol Exp Ther 271 : 1253 1258.
8. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 : 3099 3108.
9. Deupree JD, Hinton KA, Cerutis DR, Bylund DB (1996). Buffers differentially alter the binding of 3Hrauwolscine and 3HRX821002 to the alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther 278 : 1215 1227.
10. Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB (1992). Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem 267 : 15795 15801.
11. Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006). Pharmacogenomics and individualized drug therapy. Annu Rev Med 57 : 119 137.
12. Gilsbach R, Brede M, Beetz N, Moura E, Muthig V, Gerstner C et al. (2007). Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction. Cardiovasc Res 75 : 728 737.
13. Hajjar RJ, MacRae CA (2002). Adrenergic-receptor polymorphisms and heart failure. N Engl J Med 347 : 1196 1199.
14. Hein L, Altman JD, Kobilka BK (1999). Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402 : 181 184.
15. Johnson JA, Lima JJ (2003). Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 13 : 525 534.
16. Johnson RA, Toews ML (1990). Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells. Mol Pharmacol 37 : 296 303.
17. Kable JW, Murrin LC, Bylund DB (2000). In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 293 : 1 7.
18. Kobilka B (1992). Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15 : 87 114.
19. Kukkonen JP, Renvaktar A, Shariatmadari R, Akerman KE (1998). Ligand- and subtype-selective coupling of human alpha-2 adrenoceptors to Ca++ elevation in Chinese hamster ovary cells. J Pharmacol Exp Ther 287 : 667 671.
20. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, Dupont WD, Scheinin M et al. (2008). Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension 51 : 406 411.
21. Li JL, Canham RM, Vongpatanasin W, Leonard D, Auchus RJ, Victor RG (2006). Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks? Hypertension 47 : 1140 1146.
22. Limbird LE (1988). Receptors linked to inhibition of adenylate cyclase: additional signalling mechanisms. FASEB J 2 : 2686 2695.
23. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ (2007). Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 13 : 315 323.
24. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE (1996). Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273 : 801 803.
25. Materson BJ, Reda DJ (1994). Correction: single-drug therapy for hypertension in men. N Engl J Med 330 : 1689.
26. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS et al. (1993). Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328 : 914 921.
27. Maudsley S, Martin B, Luttrell LM (2005). The origins of diversity and specificity in g protein-coupled receptor signalling. J Pharmacol Exp Ther 314 : 485 494.
28. Petrash AC, Bylund DB (1986). Alpha-2 adrenergic receptor subtypes indicated by 3Hyohimbine binding in human brain. Life Sci 38 : 2129 2137.
29. Pohjanoksa K, Jansson CC, Luomala K, Marjamaki A, Savola JM, Scheinin M (1997). Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol 335 : 53 63.
30. Regitz-Zagrosek V, Hocher B, Bettmann M, Brede M, Hadamek K, Gerstner C et al. (2006). Alpha2C-adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy. Eur Heart J 27 : 454 459.
31. Rosskopf D, Michel MC (2008). Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. Pharmacol Rev 60 : 513 535.
32. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M (1998a). Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 18 : 3035 3042.
33. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M (1998b). D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype. Neuroscience 86 : 959 965.
34. Sallinen J, Haapalinna A, Macdonald E, Viitamaa T, Lahdesmaki J, Rybnikova E et al. (1999). Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol Psychiatry 4 : 443 452.
35. Sastre M, Garcia-Sevilla JA (1994). Alpha 2-adrenoceptor subtypes identified by 3HRX821002 binding in the human brain: the agonist guanoxabenz does not discriminate different forms of the predominant alpha 2A subtype. J Neurochem 63 : 1077 1085.
36. Shimizu H, Daly JW, Creveling CR (1969). A radioisotopic method for measuring the formation of adenosine 3′,5′-cyclic monophosphate in incubated slices of brain. J Neurochem 16 : 1609 1619.
37. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB (2000). A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275 : 23059 23064.
38. Small KM, McGraw DW, Liggett SB (2003). Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43 : 381 411.
39. Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, Liggett SB (2004). Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci USA 101, 13020 13025.
40. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K (2003). All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol 368 : 504 512.
41. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Wreinstein H et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320 : 1 13.
42. Vrydag W, Alewijnse AE, Michel MC (2009). Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors? Br J Pharmacol 156 : 127 134.
43. Wallace DR, Muskardin DT, Zahniser NR (1994). Pharmacological characterization of 3Hidazoxan, 3HRX821002 and p-125Iiodoclonidine binding to alpha 2-adrenoceptors in rat cerebral cortical membranes. Eur J Pharmacol 258 : 67 76.
44. Woodiwiss AJ, Badenhorst D, Sliwa K, Brooksbank R, Essop R, Sareli P et al. (2008). Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry. Cardiovasc J Afr 19 : 188 193.